All In Biotech

Drugs by condition

Drugs approved for alopecia areata

Brand-name prescription drugs and biologics whose FDA label lists alopecia areata as an approved use. Matched on the label phrases: "alopecia areata".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

6

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

4

New molecular entities and new biologics

In development

10

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for alopecia areata.

  • Leqselvi (Deuruxolitinib Phosphate) · Sun Pharm Inds INC NovelJul 25, 2024
  • Litfulo (Ritlecitinib Tosylate) · Pfizer NovelJun 23, 2023
  • Olumiant (Baricitinib) · Eli Lilly and CO NovelBreakthrough therapyMay 31, 2018
  • Celestone Soluspan (Betamethasone Acetate, Betamethasone Sodium Phosphate) · Organon NovelMar 3, 1965
  • Kenalog-10 (Triamcinolone Acetonide) · Apothecon Jan 4, 1960

All approved drugs for alopecia areata, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 20 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Janus Kinase Inhibitor (1)

  • Olumiant Baricitinib · Eli Lilly and CO · 2018

Corticosteroid (1)

  • Kenalog-10 Triamcinolone Acetonide · Apothecon · 1960

Class not listed in FDA's data (4)

  • Leqselvi Deuruxolitinib Phosphate · Sun Pharm Inds INC · 2024
  • Litfulo Ritlecitinib Tosylate · Pfizer · 2023
  • Celestone Soluspan Betamethasone Acetate, Betamethasone Sodium Phosphate · Organon · 1965
  • Depo-Medrol Methylprednisolone Acetate · Pfizer · 1959

Drugs in development for alopecia areata

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • VC005Phase 35 trials

    Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis

  • RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials

    Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata

  • SYHX1901Phase 32 trials

    CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata

  • CTP-543Phase 31 trial

    Sun Pharmaceutical Industries, Inc. · Alopecia Areata

  • IMG-007Phase 23 trials

    Inmagene LLC · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema

  • ADX-914bempikibartPhase 22 trials

    Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata

  • LY4005130Phase 22 trials

    Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)

  • ALD-102Phase 21 trial

    Aldena Therapeutics · Alopecia Areata (AA)

  • LAD603Phase 21 trial

    Almirall, S.A. · Alopecia Areata

  • NXC736Phase 21 trial

    NEXTGEN Bioscience · Alopecia Areata

More on alopecia areata: recruiting trials · published research

Related in immunology and inflammation: Rheumatoid arthritis · Plaque psoriasis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Ankylosing spondylitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.